The Renin Angiotensin System in Essential Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12415112

Enrollment

Registered

2006-09-29

Start date

2001-12-03

Completion date

Unknown

Last updated

2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular: Essential hypertension Circulatory System Essential (primary) hypertension

Interventions

Randomised crossover trial

Eligibility

Inclusion criteria

Inclusion criteria: 11 subjects and 11 controls

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
This research is based on the increasing evidence that blockade of the renin-angiotensin-aldosterone system has benefits additional to a fall in blood pressure. There are two major ways of blocking the renin-angiotensin system (RAS), either by inhibiting the enzyme that generates angiotensin II or by blocking the angiotensin receptor, that medicates most of the actions of angiotensin II on its target tissues. The original and existing aim of this study is to compare the effects of enalapril, an angiotensin converting enzyme inhibitor, against candesartan, a potent and specific angiotensin II receptor blocker, in both normotensive and hypertensive subjects on a normal and moderate sodium restricted diet. Assessment of the contribution of the RAS to blood pressure control and of the mechanism whereby blood pressure falls, will provide important information about the maintenance of blood pressure.	—

Measure

Time frame

This research is based on the increasing evidence that blockade of the renin-angiotensin-aldosterone system has benefits additional to a fall in blood pressure. There are two major ways of blocking the renin-angiotensin system (RAS), either by inhibiting the enzyme that generates angiotensin II or by blocking the angiotensin receptor, that medicates most of the actions of angiotensin II on its target tissues. The original and existing aim of this study is to compare the effects of enalapril, an angiotensin converting enzyme inhibitor, against candesartan, a potent and specific angiotensin II receptor blocker, in both normotensive and hypertensive subjects on a normal and moderate sodium restricted diet. Assessment of the contribution of the RAS to blood pressure control and of the mechanism whereby blood pressure falls, will provide important information about the maintenance of blood pressure.

—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026